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Prophylactic DNA vaccines against the influenza virus are promising alternatives to conventional vaccines. In this study, we 
generated two candidate gene-based influenza vaccines encoding either the seasonal or pandemic hemagglutinin antigen (HA) 
from the strains A/New Caledonia/20/99 (H1N1) (pV1A5) and A/California/04/2009 (H1N1) (pVEH1), respectively. After 
verifying antigen expression, the immunogenicity of the vaccines delivered intramuscularly with electroporation was tested in 
a mouse model. Sera of immunized animals were tested in hemagglutination inhibition assays and by ELISA for the presence 
of HA-specific antibodies. HA-specific T-cells were also measured in IFN-γ ELISpot assays. The protective efficacy of the 
candidate influenza vaccines was evaluated by measuring mortality rates and body weight after a challenge with 100 LD50 of 
mouse-adapted A/New Caledonia/20/99 (H1N1). Mice immunized with either one of the two vaccines showed significantly 
higher T cell and humoral immune responses (P<0.05) than the pVAX1 control group. Additionally, the pV1A5 vaccine effec-
tively protected the mice against a lethal homologous mouse-adapted virus challenge with a survival rate of 100% compared 
with a 40% survival rate in the pVEH1 vaccinated group (P<0.05). Our study indicates that the seasonal influenza DNA vac-
cine completely protects against the homologous A/New Caledonia/20/99 virus (H1N1), while the pandemic influenza DNA 
vaccine only partially protects against this virus.  
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A new influenza A subtype H1N1 recently emerged, caus-
ing a human pandemic. Vaccination is the most effective 
measure to control the spread of the virus and to reduce the 
associated morbidity and mortality. However, existing evi-
dence shows that the formerly used trivalent seasonal influ-
enza vaccines are unlikely to provide protection against the 
new virus strain. Therefore, the development of new vac-
cines to protect against this virus is urgently needed. 
Immunization with inactivated vaccines has long been 
the main method used for preventing influenza infections. 
However, approaches other than conventional vaccines have 
also been found to induce protective immunity against im-
portant structural proteins of the H1N1 virus. Promising 
approaches include recombinant protein vaccines [1], ade-
novirus-based technologies [2] and DNA plasmids [3]. 
Plasmid DNA vaccines are non-pathogenic, stable at ambi-
ent temperatures, economical to produce, and they can be 
used for repeated immunizations. Many studies in chicken 
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and mice have shown that DNA vaccines can provide pro-
tection against influenza subtypes H1, H3, H5, H7, and  
H9 [4–8]. In particular, DNA vaccines that express the he-
magglutinin (HA) protein can protect mice from the viral 
challenge of either influenza A or B [9−13]. As well as the 
choice of vaccine antigen, the method of delivery of the 
vaccines can also influence their effectiveness. Recent ani-
mal studies suggest that DNA vaccines can be delivered by 
in vivo electroporation (EP), resulting in high transfection 
efficiency and increased protein expression [14,15]. EP re-
quires the application of short electrical pulses to the target 
tissue, rendering the cell membrane transiently permeable to 
DNA and other molecules. The effectiveness of EP as a 
non-viral gene delivery tool and its capacity for enhancing 
the potency of DNA vaccines have been demonstrated. Fur-
thermore, EP has been frequently and successfully used to 
augment the potency of muscle-targeted DNA vaccines.  
Heterosubtypic immunity (HSI) is defined as cross-pro-     
tection against infection with an influenza A serotype other 
than the one used for primary infection or immunization. 
HSI is thought to be mediated by serotype cross-reactive 
cytotoxic T lymphocytes (CTL) that recognize the con-
served epitopes of structural proteins. However, recent 
studies suggest that antibodies may also have a significant 
role in HIS [16]. In this study, we assess the protection af-
forded by DNA vaccines expressing different H1N1 HAs 
delivered by electroporation against a lethal challenge with 
seasonal A/New Caledonia/20/99 (H1N1) influenza virus in 
a mouse model. 
1  Materials and methods 
1.1  Viruses and cells  
The A/New Caledonia/20/99 (H1N1) influenza virus (Gen-
Bank ID: CY033622) was stored in our laboratory. The 
A/New Caledonia/20/99 (H1N1) influenza virus that had 
been repeatedly passaged lung-to-lung and adapted in mice 
was propagated in 10-day-old embryonated specific-patho-    
gen-free chicken eggs at 37°C and stored at −70°C. Viruses 
were titrated using the Reed and Muench method to deter-
mine the median tissue culture infective dose (TCID50 = 
10−6.25/0.05 mL) and then used to challenge Balb/c (12 weeks 
old) mice to determine the median lethal dose (LD50 = 
10−3.5/0.05 mL). Baby hamster kidney (BHK-21) cells were 
used for the transient expression experiments. All experi-
ments using the A/New Caledonia/20/99 (H1N1) virus, in-
cluding the animal challenge experiments, were conducted 
in accordance with biosafety level 2 containment proce-
dures. 
1.2  Plasmid constructions 
Two different versions of the HA gene (A/New Caledo-
nia/20/99 (H1N1), GenBank ID: CY033622 and A/Cali-     
fornia/07/2009 (H1N1), GenBank ID: GQ117044) were 
cloned into plasmid vectors. The HA gene of A/New Cale-
donia/20/99 (H1N1) was obtained by RT-PCR amplification 
with primers to introduce Nhe I and Xho I restriction sites 
and a Kozak sequence. The HA gene of A/California/07/    
2009 (H1N1) was commercially synthesized (TaKaRa, Da-
lian, China). The HA genes of these two strains were ligated 
into the pVAX1 expression vector (Invitrogen, Carlsbad, 
CA, USA) at the Nhe I and Xho I restriction sites, resulting 
in rDNA vector vaccines pV1A5 (A/New Caledonia/20/99 
(H1N1)) and pVEH1 (A/California/04/2009 (H1N1)). The 
nucleotide sequences of both HA genes were confirmed 
using the ABI PRISM 377XL DNA Sequencer (Applied 
Biosystems Foster City, CA, USA). The plasmids were 
propagated in Escherichia coli JM109, and the DNA was 
extracted using the Plasmid Maxi Kit (Omega Bio-Tek, 
Doraville, CA, USA). The purified DNA was resuspended 
in sterile saline solution and stored at −20°C until it was 
used. 
1.3  Indirect immunofluorescence assay for immuno-
genicity 
BHK-21 cells were transfected with purified pV1A5, 
pVEH1, and pVAX1 DNA using Lipofectamine 2000 (In-
vitrogen) in accordance with the manufacturer’s protocol. 
Briefly, cell monolayers were grown on glass coverslips in a 
six-well plate and then transfected with the plasmid DNA 
(10 μg/well). Forty-eight hours after transfection, the cells 
were fixed with 0.05% glutaraldehyde and permeabilized 
with 0.5% Triton X-100 in phosphate-buffered saline (PBS), 
followed by incubation with rabbit polyclonal antibody spe-
cific for the HAs of A/New Caledonia/20/99 (H1N1) and 
A/California/07/2009 (H1N1) (1:2000 in poly(butylene 
succinate-co-terephthalate) (PBST)) for 1 h at 37°C. Fluo-
rescein isothiocyanate (FITC)-conjugated goat anti-rabbit 
IgG antibodies (1:1000) with Evans Blue (1:200) diluted in 
PBS/bovine serum albumin (BSA) were added and then 
incubated for 1 h at room temperature. After mounting the 
samples, fluorescence images were scanned using an 
Olympus microscope (BX51; Olympus, Tokyo, Japan). 
1.4  DNA immunization and in vivo electroporation 
Immunization of three groups of six to eight-week-old fe-
male Balb/c mice (n=15 in each group) was performed by 
intramuscular injection of plasmid DNA (100 μg of plasmid 
DNA in 100 μL of PBS (pH 7.4) at two leg sites in the gas-
trocnemius muscle of each mouse) using a milliliter gauge 
needle. After injection, a pair of electrode needles 5 mm 
apart was inserted into the muscle at the DNA injection site, 
and electric pulses were delivered using an electric pulse 
generator (Genetronics, San Diego, CA, USA) [17]. EP 
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pulses (three unipolar pulses of 5 Hz at 75 V, 20 ms each 
time,) were delivered using an ECM 830 square wave pulse 
generator (BTX, San Diego, CA, USA). At the end of the 
third week, each group received one booster immunization 
identical to the first immunization. Blood samples were 
taken at one, two, three, and five weeks after primer immu-
nization for determination of antibody titers. 
1.5  Virus challenge in mice 
To assess the efficacy of the two candidate vaccines against 
lethal infection, the immunized mice were anesthetized two 
weeks after the second immunization and intranasally chal-
lenged with 100 LD50 of the A/New Caledonia/20/99 
(H1N1) virus in a final volume of 50 μL. DNA plasmid 
vectors (pVAX1) lacking an insert were used as a negative 
control. All studies with the live A/New Caledonia/20/99 
(H1N1) virus were performed in accordance with the guide-
lines of the National Institutes of Health and the Centers for 
Disease Control and Prevention (www.cdc.gov/flu/h2n2bsl3. 
htm). After infection, the mice were observed every day for 
14 d, and survival and clinical parameters such as body 
weight were recorded. Tissue homogenates were prepared 
by mechanical disruption of the lungs removed from the 
dead mice under sterile conditions and used for the RT-PCR 
assay. The HA gene was amplified and cloned into the 
pMD18-T vector for sequencing.  
1.6  Enzyme-linked immunosorbent assay 
Samples collected on zero, seven, 14, 21, and 35 d post-      
immunization were used to detect IgG antibodies by indirect 
enzyme-linked immunosorbent assay (ELISA) as previously 
described [18]. Briefly, 96-well plates (Costar, Cambridge, 
Mass, USA) were coated with 50 ng of inactivated A/New 
Caledonia/20/99 (H1N1) virus at 4°C overnight, and an 
ELISA kit for detecting mouse A/California/07/2009 (H1N1) 
H1HA IgG antibody was used (Cusabio Biotech). Anti-
gen-coated immunoassay plates were washed five times 
with wash buffer and then blocked with 1% BSA in PBS for 
1 h at 37°C. The serum samples were diluted 100 times in 
PBS containing 0.5% (w/v) gelatin, 0.15% Tween 20, and 
4% calf serum (ELISA diluent) and applied in duplicate 
wells and incubated for 1 h at 37°C. The plates were washed 
five times with PBS and then reacted with 1:2000 dilutions of 
HRP-labeled goat anti-mouse IgG (Zhongshan-Golden 
Bridge Biotech Co., Ltd., Beijing, China) for 1 h at 37°C. 
After another five washes with PBS, the substrate (10 mg 
ortho-phenylenediamine+20 mL 0.015% hydrogen peroxide 
in phosphate/citrate buffer) was added. After incubation for 
15 min at 37°C, the reactions were terminated with 2N H2SO4. 
The absorbance values were determined at 492 nm using a 
Sunrise automated plate spectrophotometer and analyzed 
with Microsoft Excel 2007 for Windows. P-values were cal-
culated to identify significant differences between the groups. 
1.7  Hemagglutination inhibition test 
Five mice per group were euthanized five weeks after the 
first immunization. Sera were collected, treated with recep-
tor destroying enzyme (RDE) (Denka-Seiken) and incu-
bated overnight at 37°C prior to being tested. Samples were 
then heat-inactivated at 56°C for 30 min. Serum samples 
were serially diluted two-fold using v-bottom microtiter 
plates. Equal volumes of 4 HA units of seasonal influenza 
A/New Caledonia/20/99 (H1N1) virus and A/California/07/ 
2009 (H1N1) HA antigen as the source of antigen were 
added to each well. The plates were mixed by agitation, 
covered, and allowed to settle for 30 min at room tempera-
ture. Subsequently, 50 μL of 1% chicken red blood cells 
were added and incubated for 15 min at 37°C. The hemag-
glutination inhibition (HI) titer was determined by recipro-
cal dilution of the row that contained non-agglutinated 
chicken red blood cells. Positive and negative serum con-
trols were included in each plate [19]. 
1.8  Ex vivo interferon (IFN)-γ ELISpot assay  
The level of cellular immunity stimulated by DNA vaccina-
tion was evaluated by measuring the frequency of interferon 
IFN-γ secreting splenocytes using a mouse IFN-γ ELISpot 
assay in accordance with the manufacturer’s instructions 
(Dakewe Biotech, China). Dilutions of splenocytes from 
each mouse (106 cells/well) were distributed in polyvi-
nylidene difluoride-treated 96-well plates that were previ-
ously coated with an anti-mouse IFN-γ monoclonal anti-
body. Mice splenocytes were added in triplicate with an 
input cell number of 1×106 cells/well in 100 μL of 1640 
medium with 10% fetal bovine serum (FBS). The inacti-
vated whole A/New Caledonia/20/99 (H1N1) virus and the 
A/New Caledonia/20/99 (H1N1) HA antigen were diluted 
in complete culture medium at a final concentration of   
10 μg mL−1, and 100 μL of the diluted samples was added 
to each well. Concanavalin A (ConA) (5 μg mL−1) was used 
as a positive control, and cells resuspended in complete cul-
ture medium only served as a negative control. After 
overnight incubation in a CO2 incubator at 37°C, the 
splenocytes were discarded from the plates which were then 
extensively washed with precooled H2O. The IFN-γ spots 
were detected by biotinylated anti-mouse IFN-γ specific an-
tibody. Streptavidin-horseradish peroxidase (HRP) was added 
and the plates were developed with 3-amino-9-ethylcarbazole 
(AEC) substrate solution. The spots were counted using an 
automated ELISpot reader (Bioreader 4000 PRO, Biosys, 
Germany). The results were expressed as mean±SEM of the 
number of spot-forming cells (SFC)/106 spleen cells.  
1.9  Statistical analysis  
The immune response of individual animals was evaluated 
for statistical analysis. The significance of the cellular and 
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humoral immune responses was determined by two-way 
ANOVA with P-values generated using GraphPad 5.0 
software. The Mantel-Cox test was used to evaluate the lev-
els of protective immunity between groups. Differences 
were considered significant when the P-value was <0.05. 
2  Results 
2.1  Construction of expression plasmids and the in 
vitro assessment of immunogenicity 
To determine the immunogenicity of the candidate influ-
enza HA DNA vaccines, plasmids expressing the HAs of 
A/New Caledonia/20/99 (H1N1) and A/California/07/2009 
(H1N1) were constructed and verified by sequencing as 
described in section 1.2 above. The expression of the HA 
proteins by pV1A5, pVEH1, and pVAX1 48 h after trans-
fection of BHK-21 cells was detected by an immunofluo-
rescence assay with anti-HA serum. The results, shown in 
Figure 1, indicate that the pV1A5 and pVEH1 plasmids 
were successfully constructed and express the correspond-
ing HA proteins. Thus, confirming that the plasmids were 
suitable for use in subsequent experiments. 
2.2  Induction of antibody responses in mice immu-
nized with the HA DNA vaccines 
To compare the abilities of the two DNA vaccines to induce 
HA-specific immune responses, serum samples were ob-
tained from all the mice five weeks after the first immuniza-
tion and screened for H1N1 IgG specific antibodies and HI 
antibodies against A/New Caledonia/20/99 (H1N1) and 
A/California/07/2009 (H1N1) HA antigens. HA-specific 
antibodies were detected in the animals that were immu-
nized with pVEH1 and pV1A5. Remarkably, with four HA 
units of the A/New Caledonia/20/99 (H1N1) virus, the 
pV1A5 group mean HI titer was 79, about 12 times higher 
than the titer of the pVEH1 group (Figure 2A). With four 
HA units of the A/California/07/2009 (H1N1) HA antigen, 
the titer of the pV1A5 group was 4.3 times less than that of 
the pVEH1 group (Figure 2B). 
 
 
Figure 1  Detection of HA expression by DNA vaccine vectors using 
indirect immunofluorescence. Green fluorescence of the expressed HA 
proteins was observed under a fluorescence microscope in BHK-21 cells 
transfected with pVEH1 (A) or pV1A5 (B). No fluorescence signal was 
observed in control cells (data not shown) or in BHK-21 cells (C) trans-
fected with pVAX1. To clearly distinguish between cells expressing the 
HA protein and those that are not, Evans Blue mixed with FITC-conju-    
gated goat anti-rabbit IgG antibodies was used. The red cells are those that  
do not express the HA protein. 
The IgG antibodies were detected using indirect ELISA 
with the A/New Caledonia/20/99 (H1N1) inactivated whole 
virus as the coated antigen. The absorbance of samples from 
mice immunized with pV1A5 rose from 0.27, 7 d post in-
oculation (7 DPI) to 0.46, 14 DPI and then slightly de-
creased 21 DPI. After receiving the booster dose, the titer 
rapidly increased to 0.68, 35 DPI. The mice in the pVEH1 
immunized group only presented mild changes in antibody 
titers, with the maximum absorbance level corresponding to 
that of the pV1A5 group 14 DPI. The exception was at 7 
DPI when the level of HA-specific IgG antibodies in the 
pV1A5 DNA vaccine immunized group was higher than 
that in the pVEH1 group (P<0.05). The titer of the pVEH1 
immunized group was similar to that of the pVAX1 group 
(P>0.05) except at 35 DPI (Figure 2C). The same response 
patterns were seen for the antibodies specific for 
A/California/07/2009 (H1N1) HA antigen and detected by 
ELISA. The mice in the pVEH1 immunized group showed a 
significantly higher titer than those in the pV1A5 group 
(P<0.05) except at 7 DPI (Figure 2D). No specific 
anti-H1HA antibodies were detected in the mice inoculated 
with pVAX1. The titer of the pV1A5 immunized group was 
statistically higher than that of the pVAX1 group (P<0.05) 
except at 7 DPI. These results indicate that, after primary 
intramuscular vaccination with in vivo electroporation, the 
DNA vaccine expressing the HA protein significantly in-
duces specific antibody responses at 14 DPI. Furthermore, 
the IgG antibody levels induced by the two candidate vac-
cines showed low levels of cross-protection to the het-
erologous subtype viruses. 
2.3  Cell-mediated immune responses induced in mice 
immunized with HA DNA vaccines 
Splenocytes were harvested from five immunized mice 
from each group 3 d after the boost vaccination. The ELIS-
pot assay was used to assess the magnitude of the 
HA-specific IFN-γ T cell responses after mice were vacci-
nated with the HA DNA. The harvested splenocytes were 
stimulated with A/New Caledonia/20/99 (H1N1) inactivated 
virus and A/California/07/2009 (H1N1) HA antigen for 24 h 
and scored in ELISpot assays for IFN-γ producing cells. As 
shown in Figure 3, after stimulation with the inactivated 
virus samples, the pV1A5 immunized group produced 
(353±18) spots/106 cells, which was not significantly higher 
than the (317±14) spots/106 cells produced by the pVEH1 
group (P>0.05). Following stimulation with A/California/    
07/2009 (H1N1) HA antigen the trend was similar, with the 
pVEH1 immunized group producing (275±6) spots/106 cells 
and the pV1A5 group producing (253±20) spots/106 cells. A 
low number of non-specific IFN-γ ELISpots were detected 
in both the control groups (<10/106 cell spots). The ELISpot 
background counts in wells containing splenocytes in the 
absence of nominal antigens were approximately the same 
as those in the control groups. The positive non-specific  
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Figure 2  Humoral immunity response of immunized mice. Sera were collected two weeks after the second vaccination and tested individually for HI anti-
bodies against A/New Caledonia/20/99 (H1N1) (A) and A/California/07/2009 (H1N1) HA antigen (B). HI antibody titers for individual mice are expressed 
as log2 of the reciprocal of the highest dilution of serum inhibiting the agglutination of 1% chicken erythrocytes by four HA units of the virus or HI antigens. 
Horizontal lines represent the geometric mean for each group. The IgG specific antibody response after DNA vaccination was measured by indirect ELISA 
assays that were performed using plates coated with A/New Caledonia/20/99 (H1N1) (C) or A/California/07/2009 (H1N1) HA antigen (D). Sera were col- 
lected by tail bleeding zero, one, two, three, and five weeks after the first immunization. Data are shown as mean±SEM per group. *, P<0.05. 
 
Figure 3  IFN-γ secreting splenocytes from immunized mice. Specific 
responses of the splenocytes 14 d after the second immunization were 
determined by an IFN-γ ELISpot assay using inactivated whole virus or 
A/California/07/2009 (H1N1) antigen stimulation. Data are presented as  
mean±SEM per group. SFC, spot forming cells. 
IFN-γ ELISpot response stimulated by ConA was 300 
spots/106 cells. Compared with the non-immunized control 
groups, significant numbers of HA-specific IFN-γ ELISpots 
were detected in all the immunized groups (P<0.05). These 
results demonstrate that the HA DNA vaccine induced the 
antigen-specific IFN-γ responses. The difference between 
the ELISpot responses after stimulation with either the 
A/New Caledonia/20/99 (H1N1) virus or with the A/Cali- 
fornia/07/2009 (H1N1) HA antigen was not significant 
(P>0.05).  
2.4  Protective immunity against the virulent H1N1 
influenza challenge 
At 35 DPI, three groups of mice were challenged intrana-
sally with A/New Caledonia/20/99 (H1N1) and observed 
for 14 d for clinical signs and survival rates. All animals 
immunized with the pVAX1 control experienced substantial 
weight loss beginning 2 d post-challenge and were dead 4–8 
d post-challenge. By the end of the experiment, all of the 
mice in the control group immunized with pVAX1 were 
dead. By contrast, all animals immunized with pV1A5 
showed only mild and transient loss of body weight and all 
of them survived the lethal challenge. The mice immunized 
with pVEH1 developed clinical signs such as depression 
and muscle spasms and began to die 5 d post-challenge. The 
mortality rate in the pVEH1 immunized group was 60%. 
Thus, the protective immunity of the pVEH1 vaccine was 
significantly lower than that of the pV1A5 vaccine (P<0.05). 
The percentages of mice that were protected from death or 
weight loss post-challenge are summarized in Figure 4.  
When the sequences of the viruses from the lung super-
natants of the pVEH1 and pVAX1 immunized groups were 
compared, the HA amino acid sequence of A/New Caledo-
nia/20/99 (H1N1) was found in 99.1% of the pVEH1 group 
and in 99.7% of the pVAX1 group. We were unable to am-
plify an HA positive band from the lung tissue of the mice 
in the pV1A5 group. 
3  Discussion 
Prophylactic vaccination prior to the epidemic flu season is 
an efficient way to control influenza virus infections. The 
currently licensed trivalent inactivated influenza vaccines  
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Figure 4  Immune protection conferred by the HA DNA vaccines against the lethal challenge. A, Survival in mice (n=10 mice/group) challenged by intra-
nasal inoculation with 100 LD50 of A/New Caledonia/20/99 (H1N1) influenza virus two weeks after the second immunization. *, P<0.05. B, Weight loss in  
the same challenged group of mice. Mean weight loss is expressed as a percentage of their original weight. Data shown are the mean for 10 mice per group. 
have proven to be ineffective in conferring protection dur-
ing epidemic influenza seasons when the vaccine and circu-
lating strains are not well-matched antigenically. To control 
the pandemic influenza virus, plasmid DNA vaccines have 
been considered as an alternative to the inactivated vaccines. 
Previous research has shown that DNA vaccines expressing 
the H1, H3, H5, H7, and H9 subtypes can protect mice, 
chickens, and swine against a challenge from a homologous 
influenza virus [7,8,20–24]. In this study, we investigate 
whether DNA vaccines can protect against a heterologous 
viral challenge. 
The HA protein is the principal component of the spikes 
on the viral envelope that mediate the binding of virus par-
ticles to cell-surface receptors and trigger subsequent entry 
into the host cell [25]. Therefore, immunity against the HA 
antigen can be expected to confer a high level of protection 
against influenza. Several types of HA-based vaccines have 
been shown to protect against a challenge from influenza 
virus of the same HA subtype [26]. 
In this study, two gene-based DNA vaccines expressing 
the HA protein of A/New Caledonia/20/99 (H1N1) and 
A/California/07/2009 (H1N1) were constructed and their 
abilities to protect against a seasonal A/New Caledonia/20/   
99 (H1N1) challenge in a mouse model were assessed. 
Consistent with previous research, electroporation-assisted 
immunization with these two DNA vaccines elicited strong 
cellular and humoral immune responses to the correspond-
ing virus [27,28]. We initially compared the traditional 
DNA immunization method with electroporation delivery 
immunization. The groups that were immunized using elec-
troporation showed significantly higher levels of both hu-
moral and cell-mediated immunity than the groups immu-
nized in the traditional way (data not shown). The humoral 
immune response of the pV1A5 immunized group was 
enough to neutralize the A/New Caledonia/20/99 (H1N1) 
virus challenge, indicating that the antibodies that were 
produced were necessary and sufficient to confer protective 
immunity to a lethal challenge with the homologous virus. 
By contrast, the pVEH1 vaccine encoding the pandemic 
influenza virus HA protein gave a protective rate of 40% to 
the immunized group challenged with the identical seasonal 
influenza virus. This result indicates that the pVEH1 vac-
cine did not completely protect the mice against the het-
erologous subtype challenge. The level of IgG and HI anti-
bodies in this group shows that the heterologous cross-pro-     
tective immunity was low compared with homologous virus 
stimulation.  
The ELISpot assay was used to assess the magnitude of 
HA-specific IFN-γ T cell responses to stimulation with dif-
ferent antigens. The immunogenic T cell epitopes may be 
conserved in the seasonal and pandemic H1N1 influenza 
viruses because the cell-mediated immune responses to 
A/New Caledonia/20/99 (H1N1) in the two immunized 
groups were not significantly different (P>0.05). This result 
is consistent with a previous report that indicated that half 
of the predicted CTL epitopes within a swine-origin influ-
enza virus (H1N1) HA are also present in the conventional 
influenza HA vaccine [29]. The results of the ELISpot assay 
indicate that, while the humoral immune responses show a 
significant difference (P<0.05), the levels of cellular 
cross-protective immunity elicited by the two candidate 
vaccines are not significantly different (P>0.05). The mean 
HI antibody titer of the pVEH1 immunized group against 
the A/New Caledonia/20/99 (H1N1) antigen was 65 and 
significantly lower than that of the pV1A5 immunized 
group with a mean titer of 79. The same trend was observed 
for the IgG antibodies. This result may be explained by the 
80.1% amino acid homology between the two H1N1 viral 
HA proteins, and by antigenic drift that greatly influences 
the protective immunity against A/New Caledonia/20/99 
(H1N1). 
Based on our experimental results, we conclude that dif-
ferences in the humoral immune response may be responsi-
ble for the relatively lower protection that was observed 
against the heterologous subtype challenge. The HA amino 
acid sequences of the A/California/07/2009 (H1N1) and 
A/New Caledonia/20/99 (H1N1) viruses differ by 19.9%. 
As suggested earlier [16], a difference of this magnitude 
may be enough to qualify as an “antigenic drift”, allowing 
the virus to spread to a pandemic level. 
The novelty of the present work is based on two factors. 
First, we used an electroporation delivery method of immu-
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nization to test our DNA candidate vaccines against influ-
enza. Second, we compared the levels of cross-protective 
immunity of seasonal and pandemic influenza HA based 
DNA vaccines in vivo and in vitro by challenges with lethal 
doses of seasonal influenza virus. Our study validates the 
utility of electroporation for DNA immunizations and dem-
onstrates the protective efficacy of HA based DNA vaccines 
against influenza. 
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